We build trust in the safety of vaccines through rigorous science.
Case Definitions
This report introduces a Brighton Collaboration (BC) case definition for autoimmune hepatitis (AIH), which has been classified as a priority adverse event of[...]
This is a revision of the online November 2021 Brighton thrombosis with thrombocytopenia syndrome (TTS) case definition and a new Brighton Collaboration case[...]
This deliverable collates into a single document the SPEAC Spontaneous Abortion and Ectopic Pregnancy resources, including the ICD9/10-CM, MedDRA and SNOMED codes, background[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This document includes a Brighton Collaboration case definition of the term “Sensorineural Hearing Loss” (SNHL) as well as guidelines for data collection, analysis,[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Preterm Birth and Assessment of Gestational Age. This and other companion guides have been created as[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a Brighton Collaboration case definition of the term “Vaccine-associated Enhanced Disease” (VAED) to be utilized in the evaluation of adverse events[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Thrombosis and Thromboembolism. This and other companion guides have been created as part of the CEPI-funded SPEAC project.[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a revision of the Brighton Collaboration Case Definition of the term “Anaphylaxis” to be utilized in the evaluation of adverse events[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a Brighton Collaboration Case Definition of the term “Myocarditis” and “Pericarditis” to be utilized in the evaluation of adverse events following[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Generalized Convulsion. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Anaphylaxis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Facial Nerve Palsy. This and other companion guides have been created as part of the CEPI-funded SPEAC project.[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Acute Disseminated Encephalomyelitis (ADEM). This and other companion guides have been created as part of the CEPI-funded SPEAC[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Acute Encephalitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Thrombocytopenia. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They contain[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Aseptic Meningitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Guillain Barré and Miller Fisher Syndromes. This and other companion guides have been created as part[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a The Brighton Collaboration Case Definition of the term “Acute Respiratory Distress Syndrome (ARDS)” to be utilized in the evaluation of[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This is a Brighton Collaboration Case Definition of the terms “Multisystem Inflammatory Syndrome in Children (MIS-C)” and “Multisystem Inflammatory Syndrome in Adults (MIS-A)”[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
This post contains the Companion Guide for Acute Myelitis. This and other companion guides have been created as part of the CEPI-funded SPEAC project. They[...]
-
View Companion Guide
-
View Pictorial Diagram
-
-
Vaccine Safety Templates
This manuscript uses the BRAVATO template to report the key considerations for a benefit-risk assessment of the coronavirus disease 2019 (COVID-19) mRNA-based vaccine[...]
This paper uses a BRAVATO protein template to review the features of Novavax’s recombinant adjuvanted spike protein vaccine to prevent disease caused by[...]
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has[...]
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology[...]
Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development.[...]
The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological[...]
This paper uses a BRAVATO protein template to review the features of Medigen’s recombinant SARS-CoV-2 spike protein in prefusion stabilized form used to[...]
The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform[...]
This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical[...]
This paper uses a BRAVATO nucleic acid template to review the features of Moderna’s rapid-response proprietary vaccine platform based on an mRNA delivery[...]
Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum[...]
Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC) Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as[...]
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared[...]
Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working[...]
This tool was aimed at identifying potential major hurdles or gaps that would need to be addressed during the development of vectored vaccines.[...]
In this paper, we use a standardized template describing key characteristics of the novel rVSV vaccine vectors, in comparison to wild type VSV. The template[...]
In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in comparison to the parental[...]
News
Much has been learned about the need for vaccine safety surveillance through COVAX and other recent collaborative efforts. Here, we highlight three recent[...]
The proposed IDT Modified Vaccinia virus Ankara viral vector vaccine manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of[...]
The proposed Clover COVID-19 recombinant protein vaccine manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy)[...]
The World Health Organization (WHO) has reported a ten-fold increase in dengue cases over the past twenty years. Today, nearly 4 billion people[...]
[caption id="attachment_7339" align="alignright" width="300"] Dr. Eileen Farnon, Research Director at Brighton Collaboration The Task Force for Global Health welcomes Dr. Eileen Farnon as[...]
The Vaccine Safety Working Group (VSWG) of COVAX was formed in November 2020 with representatives and consultants representing multiple stakeholders, including Brighton Collaboration,[...]
Vaccine safety data can help build public confidence in vaccines by communicating that the benefits outweigh the risks of immunization. Through the COVID-19 Safety[...]
Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals 19 February 2024—The Global Vaccine Data Network (GVDN) assessed[...]
The proposed mRNA BioNTech/Comirnaty manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Working Group encourages the Brighton[...]
The multimillion-dollar global initiative will study causes and risk factors, to ensure safer vaccines are ready for the next potential pandemic. EDMONTON —[...]
This editorial by Dr. Robert T. Chen first appeared in the October 2023 issue of Safety by Numbers. It is reposted here with permission from[...]
Dear Brighton Collaboration members: Please find below a draft Brighton Collaboration case definition for both TTS (thrombosis and thrombocytopenia syndrome) and VITT (vaccine-induced[...]
This editorial was previously published in Vaccine Safety Quarterly. Karina Top, MD, MS Karina Top, MD, MS | Principal Investigator,[...]
On behalf of the Brighton Collaboration Autoimmune Hepatitis Case Definition Working Group, please find below a manuscript on “Autoimmune hepatitis: Brighton Collaboration case[...]
On behalf of the Brighton Collaboration BRAVATO (Benefit-Risk Assessment of VAccines by TechnolOgy) Working Group, please find enclosed a manuscript and accompanying case[...]
On 8 and 9 November 2022, the Maternal Immunization Working Group (MIWG) held an in-person and online hybrid meeting. The objectives of the[...]
We are updating the Brighton website and need help from frequent users to advance requirements and provide design feedback. We will do this work[...]
The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration, based in Atlanta at The Task Force for Global Health, announced the expansion of[...]
SPEAC has completed a fifth update to the Priority List of potential Adverse events of special interest relevant to COVID-19 vaccine trials. Past[...]
We are proud to announce that Dr. Bob Chen, Scientific Director of the Brighton Collaboration, received a special award for “Contributions to Public Health[...]
